KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Payables (2016 - 2025)

Historic Payables for Arbutus Biopharma (ABUS) over the last 16 years, with Q3 2025 value amounting to $4.7 million.

  • Arbutus Biopharma's Payables fell 3832.18% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 3832.18%. This contributed to the annual value of $7.6 million for FY2024, which is 2635.58% down from last year.
  • Latest data reveals that Arbutus Biopharma reported Payables of $4.7 million as of Q3 2025, which was down 3832.18% from $4.5 million recorded in Q2 2025.
  • Arbutus Biopharma's 5-year Payables high stood at $16.0 million for Q4 2022, and its period low was $4.5 million during Q2 2025.
  • Its 5-year average for Payables is $9.4 million, with a median of $9.7 million in 2023.
  • Per our database at Business Quant, Arbutus Biopharma's Payables surged by 7007.01% in 2021 and then tumbled by 5941.66% in 2025.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Payables stood at $10.8 million in 2021, then skyrocketed by 47.9% to $16.0 million in 2022, then plummeted by 35.92% to $10.3 million in 2023, then fell by 26.36% to $7.6 million in 2024, then crashed by 38.48% to $4.7 million in 2025.
  • Its Payables stands at $4.7 million for Q3 2025, versus $4.5 million for Q2 2025 and $12.1 million for Q1 2025.